Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Deferred Taxes: 2020-2023

Historic Deferred Taxes for Oncology Institute (TOI) over the last 4 years, with FY2023 value amounting to -$76000.0.

  • Oncology Institute's Deferred Taxes rose 7174.89% to -$126000.0 in Q4 2023 from the same period last year, while for Jun 2024 it was -$126000.0, marking a year-over-year increase of 7490.04%. This contributed to the annual value of -$76000.0 for FY2023, which is 7110.27% up from last year.
  • Per Oncology Institute's latest filing, its Deferred Taxes stood at -$76000.0 for FY2023, which was up 7110.27% from -$263000.0 recorded in FY2022.
  • In the past 5 years, Oncology Institute's Deferred Taxes ranged from a high of -$76000.0 in FY2023 and a low of -$1.3 million during FY2020
  • For the 4-year period, Oncology Institute's Deferred Taxes averaged around -$731250.0, with its median value being -$752500.0 (2021).
  • In the last 5 years, Oncology Institute's Deferred Taxes surged by 758.93% in 2021 and then skyrocketed by 7882.45% in 2022.
  • Over the past 4 years, Oncology Institute's Deferred Taxes (Annual) stood at -$1.3 million in 2020, then rose by 7.59% to -$1.2 million in 2021, then soared by 78.82% to -$263000.0 in 2022, then surged by 71.1% to -$76000.0 in 2023.
  • Its Deferred Taxes stands at -$76000.0 for FY2023, versus -$263000.0 for FY2022 and -$1.2 million for FY2021.